Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...

March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced ...

Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...

TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT" or the "Company"), a clinical-stage biopharmaceutical company ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (MUN:2CL) with a Buy recommendation. There are 558 funds or institutions reporting positions in ...